Jump to content

Milk thistle drug blocks lung cancer in mice

Recommended Posts

http://today.reuters.com/news/newsArtic ... HISTLE.xml

By Martha Kerr

NEW YORK (Reuters Health) - Silibinin, a drug derived from milk thistle, destroys lung cancer in mice, investigators at the University of Colorado, Denver report in the Journal of the National Cancer Institute.

Lead investigator Dr. Rana P. Singh told Reuters Health, "We have been studying milk thistle components, silymarin and silibinin, to examine their efficacy and mechanisms against different...cancers for over a decade."

In the current study, Singh's team injected mice with a chemical called urethane to induce lung cancer. The animals then received diets containing different doses of silibinin.

"We obtained pure silibinin from Sigma Chemical Co., and silibinin diets were commercially prepared at room temperature and air dried. We did not use milk thistle dietary supplements which are available for human consumption," Singh said.

Mice fed silibinin had fewer large lung tumors than untreated mice. Further analysis showed that silibinin seemed to reduce the number of blood vessels that provide nutrients to the tumors, allowing them to grow.

Singh added that further laboratory studies of silibinin for lung cancer are now being done. "We expect soon after that clinical trials with silibinin in lung cancer patients will be planned."

Human trials of silibinin are already underway for the treatment of prostate cancer.

SOURCE: Journal of the National Cancer Institute, June 21, 2006.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.